Outcome of Dental Implant Therapy in Patients Treated With Antiresorptive Medication

Launched by COPENHAGEN UNIVERSITY HOSPITAL AT HERLEV · Feb 3, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at how well dental implants can be placed in patients who are taking medication for conditions like cancer or osteoporosis. These medications, known as antiresorptive treatments, can affect bone health, so the study aims to see if it's safe and effective to insert dental implants in these patients. The trial is currently recruiting participants of all ages and genders who have had this treatment for more than four years and have enough healthy bone to support the implants.

To be eligible for the study, participants must have a diagnosis of cancer or osteoporosis and should be able to commit to the planned assessments. They need to have an expected lifespan of at least two years and meet specific requirements regarding their overall health and bone quality. Participants can expect to undergo evaluations to determine if their jawbone is suitable for implants and will be monitored throughout the process. It’s important to note that individuals with certain health issues, like severe oral hygiene problems or specific cancer-related conditions, may not qualify for the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with cancer or osteoporosis, treated with antiresorptive treatment.
• • The patients should have sufficient compliance, this includes willingness to have the planned assessments
• • The patient should have an expected life span at enrollment of at least 2 years.
• • The local bone quality and quantity should be sufficient for implant insertion without bone augmentation and is classified according to the classification by Cawood \& Howell 1988.
• Exclusion Criteria:
• • \> 10 cigarettes daily
• • HbA1c \> 53 mmol/mol
• • Poor oral hygiene
• • Poor general condition: ECOG score 3 or 4.
• • Poor prognosis: Expected survival \<2 year is an exclusion cause.
• • Presence of metastases of the liver brain.
• • Poor local jaw bone quality acc. to Cawood classification stage 3 or 4.
• • Unwillingness to comply with the planned assessments and recordings